• Skip to main content
BC

biochimica clinica

en_US English
en_US English it_IT Italian
  • Home
  • Casi clinici
  • Ahead of print e Ultimo Fascicolo - Accedi per visualizzare gli articoli
  • Archivio BC fino a 2024
  • Sottometti un articolo
  • Norme Autori
  • Cerca

CONTRIBUTI SCIENTIFICI – Scientific Papers

Volume:

Biochimica Clinica 2018; 42(1) 32-38

Pubblicato on-line:

January 15, 2018

DOI:

10.19186/BC_2018.001

Scarica in PDF:
Autenticazione richiesta

Valutazione del sistema Optilite™ per la misura delle catene leggere libere delle immunoglobuline nel siero

AUTORI

Ilenia Infusino1,2, Simona Borille1, Mauro Panteghini1,2
1UOC Patologia Clinica, ASST Fatebenefratelli-Sacco, Milano
2Centro di Ricerca per la Riferibilità Metrologica in Medicina di Laboratorio (CIRME), Università degli Studi, Milano

ABSTRACT

Evaluation of the Optilite™ system for the determination of immunoglobulin free light chains in serum (sFLC)

The measurement of sFLCk and l and k/l ratio calculation is recommended for evaluation and management of plasma cell disorders. However, some analytical issues persist in their measurements, among which a too large long-term imprecision seems to be the main challenge. We evaluated the new Optilite system (The Binding Site) for sFLC determination by comparing its performance with specifications for bias, imprecision (as CV) and total error derived from biological variation of sFLC. We collected data during one year of routine use by employing three reagent lots. The system alignment was checked using the two-level (L and H) Optilite control material by comparing the obtained long-term experimental mean (n=233, both levels) with the manufacturer’s assigned values. The protocol for CV evaluation employed the liquid-frozen BioRad Liquichek Control and a frozen serum pool tested for 125 and 79 runs, respectively. Inaccuracy was evaluated by results of four UK-NEQAS exercises [system-specific (Optilite) consensus value as reference]. Average cumulative bias [1.1% (L) and -2.0% (H) for sFLCk; 5.4% (L) and 0.1% (H) for sFLCl, respectively] fulfilled the desirable goals. CVs for sFLCk (7.1% for Liquichek and 6.6% for the pool, respectively), sFLCl (7.8% for both Liquichek and the pool) and k/l ratio (8.9% for Liquichek and 10.2% for the pool, respectively) failed however to reach minimum quality goals. In EQAS evaluation, all sFLC k and l and 3 out of 4 k/l ratio results were within the allowable total error. In our experience, the Optilite system shows a good method alignment suitable for sFLC interpretation using fixed cut-offs. However, the assay reproducibility is probably not suitable for optimal long-term monitoring of individual patients.

BIBLIOGRAFIA

HOME
PRIVACY POLICY
5x1000 Docemus

LOGO SIBioC

EDITORE RESPONSABILE
Alberto Oliaro

EDITORIAL SECRETARY
Edizioni Minerva Medica S.p.A.
Corso Bramante 83-85, 10126 Torino
T +39 011 678282
journals.dept@minervamedica.it

Designed by Biomedia srl
© 2025 SIBioC
P. IVA IT 06484860967